Clinical Research Directory
Browse clinical research sites, groups, and studies.
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Summary
The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.
Official title: GPC3/Mesothelin Targeted CAR-γδT for Immunotherapy of Solid Cancer: Phase I Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-05-10
Completion Date
2036-12-30
Last Updated
2024-06-26
Healthy Volunteers
No
Interventions
Cell therapy for solid tumors
Transfer γδT cells into patients for anti-ancer therapy.
Locations (1)
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China